Skip to content

A verification study of enhancement of the immune system

A verification study of enhancement of the immune system with ingestion of the test food: a randomized, double-blind, placebo-controlled, parallel-group trial - A verification study of enhancement of the immune system with ingestion of the test food

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000036610
Enrollment
30
Registered
2019-04-26
Start date
2019-05-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese subjects

Interventions

Duration: 4 weeks Test food: Marrowgen Administration: Take 4 capsules of the test food with water after breakfast, lunch, and dinner * If you forget to take the test food, take it as soon as yo

Sponsors

ORTHOMEDICO Inc.
Lead Sponsor
Medical Corporation Seishinkai, Takara Clinic
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Healthy Japanese adult subjects 2. Subjects who are experiencing daily fatigue and easy to get sick 3. Subjects who are judged as eligible to participate in the study by the physician 4. Subjects who have relatively low scoring of immunological vigor at screening (before consumption)

Exclusion criteria

Exclusion criteria: 1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction 2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disease, kidney disease, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Subjects who use or take "Foods for Specified Health Uses", "Foods with Function Claims", or other functional food/beverage in daily 5. Subjects who are currently taking medications (including herbal medicines) and supplements 6. Subjects who are allergic to medicines and/or the test food related products 7. Subjects who are pregnant, lactation, or planning to become pregnant 8. Subjects who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial or plan to enroll in anther clinical trial during trial period 9. Subjects who are ineligibility to participate in the study based on the evaluation of the principal physician

Design outcomes

Primary

MeasureTime frame
Scoring of immunological vigor * Assess the measured value at screening (before consumption) and at 4 weeks after consumption or calculate the amount of change.

Secondary

MeasureTime frame
1. T lymphocyte age 2. Number of T cells 3. CD4+T cells/CD8+ T cells ratio 4. Number of naive T cells 5. Naive T cells/memory T cells ratio 6. Number of B cells 7. Number of NK cells 8. Number of CD8+CD28+T cells 9. Subjective symptoms (The Likert scale method) *1-8 Assess the measured value at screening (before consumption) and at 4 weeks after consumption or calculate the amount of change. *9 Assess the measured value at screening (before consumption) and at 4 weeks after consumption.

Countries

Japan

Contacts

Public ContactNaoko SUZUKI

ORTHOMEDICO Inc. R&D Department

nao@orthomedico.jp03-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026